The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise.
The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.
Andriole
Gerald L
GL
Division of Urologic Surgery, Washington University School of Medicine, Washington University in St. Louis, 4960 Children's Place, Campus Box 8242, St. Louis, MO 63110, USA. andrioleg@wustl.edu
Reding
Douglas
D
Hayes
Richard B
RB
Prorok
Philip C
PC
Gohagan
John K
JK
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D003110:Colonic Neoplasms / Q000175:diagnosis* / Q000401:mortality; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000401:mortality; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality; D012307:Risk Factors
D014408:Biomarkers, Tumor